Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study.

CONCLUSIONS: FDG-driven inhomogeneous dose-escalation achieves large increment in tumour and lymph node dose, while delivering similar doses to normal tissue as homogenous standard plans.
PMID: 28688525 [PubMed - as supplied by publisher]

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - July 5, 2017 Category: Radiology Authors: Møller DS, Nielsen TB, Brink C, Hoffmann L, Lutz CM, Drøgemüller Lund M, Hansen O, Schytte T, Khalil AA, Knap MM, Nyhus CH, Ottosson W, Sibolt P, Borissova S, Josipovic M, Persson G, Appelt AL Tags: Radiother Oncol Source Type: research